BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25785590)

  • 1. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
    Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
    PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
    Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
    Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOXL1-AS1 contributes to metastasis in sonic-hedgehog medulloblastoma by promoting cancer stem-like phenotypes.
    Do AD; Wu KS; Chu SS; Giang LH; Lin YL; Chang CC; Wong TT; Hsieh CL; Sung SY
    J Exp Clin Cancer Res; 2024 Apr; 43(1):130. PubMed ID: 38689348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
    Di Giulio S; Colicchia V; Pastorino F; Pedretti F; Fabretti F; Nicolis di Robilant V; Ramponi V; Scafetta G; Moretti M; Licursi V; Belardinilli F; Peruzzi G; Infante P; Goffredo BM; Coppa A; Canettieri G; Bartolazzi A; Ponzoni M; Giannini G; Petroni M
    Oncogene; 2021 Oct; 40(43):6143-6152. PubMed ID: 34508175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.
    Morrison LC; McClelland R; Aiken C; Bridges M; Liang L; Wang X; Di Curzio D; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE
    Neoplasia; 2013 Apr; 15(4):384-98. PubMed ID: 23555184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
    Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
    Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
    PLoS One; 2016; 11(7):e0154111. PubMed ID: 27367907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.
    Markant SL; Esparza LA; Sun J; Barton KL; McCoig LM; Grant GA; Crawford JR; Levy ML; Northcott PA; Shih D; Remke M; Taylor MD; Wechsler-Reya RJ
    Cancer Res; 2013 Oct; 73(20):6310-22. PubMed ID: 24067506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic role for MYCN in medulloblastoma.
    Swartling FJ; Grimmer MR; Hackett CS; Northcott PA; Fan QW; Goldenberg DD; Lau J; Masic S; Nguyen K; Yakovenko S; Zhe XN; Gilmer HC; Collins R; Nagaoka M; Phillips JJ; Jenkins RB; Tihan T; Vandenberg SR; James CD; Tanaka K; Taylor MD; Weiss WA; Chesler L
    Genes Dev; 2010 May; 24(10):1059-72. PubMed ID: 20478998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastoma stem cells.
    Fan X; Eberhart CG
    J Clin Oncol; 2008 Jun; 26(17):2821-7. PubMed ID: 18539960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.